Just a reminder about the potential for apabetalone to lower fasting glucose, insulin and HbA1c in diabetics. Reminder, all BETonMACE patients are diabetics with median dosing over 2 years. Even though Resverlogix revised their diagram to remove emphasis on glucose metabolism, don't be surprised to see glucose benefit in the full data.

From this 2014 news release:

"In the ongoing analysis of pooled ASSURE and SUSTAIN data, many biomarkers of cardiovascular risk were examined but the above findings made blood glucose levels of specific interest. Results of analysis showed that patients with DM given RVX-208 tended to have lower blood glucose vs. placebo. But specifically in patients with DM who had low HDL, the blood glucose was significantly lower following treatment with RVX-208 vs. placebo. Furthermore, the time required for RVX-208 to reduce blood glucose was not observed until at least 12 weeks following initiation of treatment."